Pregabalin (Lyzalon)
Pregabalin risk profile, scheduling, and guidance for claims professionals and care workers . Also known as Lyzalon, Pregabalin Sandoz, APO-Pregabalin, PREGABALIN-DRLA, Neuroccord and 5 more.
Pregabalin (brand names: Lyzalon, Pregabalin Sandoz, APO-Pregabalin, PREGABALIN-DRLA, Neuroccord and 5 more) is classified as Moderate risk (3 risk points) by AllMeds. It is a S4 medication under the TGA in Australia. Gabapentinoid with significant CNS depression, abuse potential, and dangerous synergy with other depressants.
Key Takeaways
- TGA Schedule: S4 in Australia
- Risk level: Moderate (3 points)
- CNS depressant: May cause sedation, impair driving, and affect work capacity
- Recommended maximum duration: 90 days
- SIRA reportable: Flagged for NSW workers compensation reporting
- PBS listed: Subsidised under the Australian Pharmaceutical Benefits Scheme
Scheduling and Classification
| Jurisdiction | Classification | Status |
|---|---|---|
| Australia (TGA) | S4 | PBS listed |
Risk Profile
Gabapentinoid with significant CNS depression, abuse potential, and dangerous synergy with other depressants.
Regulatory and Compliance Guidance
When Pregabalin appears on a claimant's medication list, claims professionals should assess whether the prescribing is appropriate for the compensable injury, whether the duration is within guidelines, and whether there are interactions with other medications on the claim.
Work capacity impact: As a CNS depressant, Pregabalin may impair driving, operating machinery, and cognitive function. Work capacity certificates should reflect any medication-related restrictions.
Australia TGA / PBS / State Schemes
Classified as S4 under the Therapeutic Goods Administration (TGA).
Listed on the Pharmaceutical Benefits Scheme (PBS) for subsidised prescribing.
Flagged as reportable under SIRA guidelines in NSW. Claims involving this medication may require additional reporting and clinical justification.
United Kingdom NICE / MHRA / FPM
NICE CG173 (Neuropathic Pain) includes pregabalin and gabapentin as treatment options for neuropathic pain. The MHRA has issued safety warnings about gabapentinoid misuse and respiratory depression risk when combined with opioids.
UK drug driving laws (Section 5A Road Traffic Act 2006) set specific limits for prescription drugs that cause impairment. Employers and occupational health advisors should assess fitness to work.
Need to assess this medication across your caseload?
Run a full risk assessment including Pregabalin interactions and compliance checks.
AllMeds gives you instant risk assessments, compliance checks, and automated letters for every medication on a claim.
Book a DemoFree trial available. No credit card required.
Medical Disclaimer: This content is for informational purposes for claims professionals and care workers. It is not medical advice. Always consult a qualified healthcare professional for clinical decisions. Drug information is sourced from TGA, FDA, MHRA, PBS, NICE, and CDC databases and may not reflect the latest updates. AllMeds does not replace clinical judgement.